University of Colorado Cancer Center, Aurora, CO
D Ross Camidge, M.D., Ph.D. more
Dr. Camidge was educated at Cambridge University (MRC Laboratory of Molecular Biology), Cambridge, UK – 1992; and Oxford University Medical School, Oxford, UK – 1995. He joined the University of Colorado as a visiting professor in November of 2005, and was recruited as full-time faculty in October of 2007.
He is the Director of the Thoracic Oncology Clinical Program and the Program Director for the Thoracic Oncology Clinical and Translational Research Fellowship - a unique training program that provides extended research exposure for U.S. or International Senior Fellows interested in Thoracic Oncology. His focus is in Thoracic Malignancies and Developmental Therapeutics (Phase I studies). In 2012 he was announced as the recipient of the 5th Bonnie J. Addario Lectureship as a ‘Luminary in the quest to eradicate lung cancer.’ In 2013 he became the first physician to receive the Hank Baskett Sr. Spirit Award, for which he was credited as being ‘one of the leading minds in lung cancer today.’
Dr. Camidge is dual-trained in medical oncology and clinical pharmacology. The Developmental Therapeutics Program acquires access to a broad range of new drugs and in conjunction with the comprehensive Thoracic Oncology Program - including a multi-disciplinary thoracic tumor board, exceptional translational science collaborators and the busy thoracic medical oncology cancer clinics - provides outstanding opportunities to develop new drugs for treating patients with thoracic malignancies. Dr. Camidge is the principal investigator on numerous national and international therapeutic trials. In addition, Dr. Camidge has written and is/has been the Principal Investigator on a number of Investigator Initiated Clinical Trials in the Thoracic Malignancies and Developmental Therapeutics programs.
CLICK HERE to see Dr. Ross Camidge in our Showcase
About University of Colorado Cancer Center
The University of Colorado Cancer Center is the Rocky Mountain region's only National Cancer Institute-designated comprehensive cancer center. NCI has given only 40 cancer centers this designation, deeming membership as "the best of the best." Headquartered on the University of Colorado Denver Anschutz Medical Campus, UCCC is a consortium of three state universities (Colorado State University, University of Colorado at Boulder and University of Colorado Denver) and six institutions (AMC Cancer Research Center, The Children's Hospital, Denver Health, Denver VA Medical Center, National Jewish Health and University of Colorado Hospital). Together, our 400+ members are working to ease the cancer burden through cancer care, research, education and prevention and control. Learn more at www.ucdenver.edu.
Participating Institutions and Investigators
Abramson Cancer Center at the Hospital of the University of Pennsylvania, Philadelphia, PA
Charu Aggarwal, MD, MPH more
Dr. Charu Aggarwal, MD, MPH is an Assistant Professor of Medicine Abramson Cancer Center at the Hospital of the University of Pennsylvania.
Dr. Aggarwal completed her medical education at Lady Hardinge Medical College, New Delhi, India, 2003 (MD) and University of Alabama at Birmingham, 2005 (for MPH in Health Care Organization and Policy).
Dr. Aggarwal then went on to complete Post-Graduate Training with an Internship and Residency in Internal Medicine at the State University of New York. She completed a Fellowship in Hematology-Oncology at Temple University-Fox Chase Cancer Center, 2008-2011 and was Chief Fellow during 2010-2011.
She holds certifications from the American Board of Internal Medicine in Internal Medicine, 2008; Hematology, 2011; and Medical Oncology, 2011.
Her professional memberships include the American Association of Cancer Research, and the American Society of Clinical Oncology.
CLICK HERE to see Dr. Charu Aggarwal in our Showcase
About the Helen F. Graham Cancer Center at Abramson Cancer Center
The Abramson Cancer Center of the University of Pennsylvania is a world leader in cancer research, patient care, and education. The pre-eminent position of the Cancer Center is reflected in its continuous designation as a Comprehensive Cancer Center by the National Cancer Institute since 1973, one of 41 such Centers in the United States.
The Abramson Cancer Center is dedicated to innovative and compassionate cancer care. The clinical program, comprised of a dedicated staff of physicians, nurse practitioners, nurses, social workers, physical therapists, nutritionists and patient care coordinators, currently sees over 90,000 outpatient visits, over 11,800 inpatient discharges, and provides over 37,000 chemotherapy treatments, and more than 66,000 radiation treatments.
In addition, the Abramson Cancer Center is home to the 400+ basic, translational and clinical scientists who work relentlessly to determine the pathogenesis of cancer. Together, the faculty are committed to improving the prevention, diagnosis and treatment of cancer. Learn more at www.penncancer.org
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Patrick Forde, MD more
Dr. Forde is Assistant Professor of Oncology in the thoracic oncology program at Johns Hopkins. He treats patients with lung cancer, mesothelioma and other thoracic cancers. He completed training in internal medicine and oncology in Ireland prior to undertaking a further fellowship at Johns Hopkins and subsequently becoming a medical oncology faculty member in the Lung Cancer Program. His research focus is in immunotherapy and, in particular, agents called anti-PD-1 antibodies which stimulate the immune system to treat cancer. These agents have shown promise in patients with advanced non-small-cell lung cancer and Dr. Forde has developed a clinical trial of anti-PD-1 for earlier stage lung cancer patients. He is active clinically, treating many patients with thoracic cancers while maintaining an active research portfolio that aims to find new and better treatments for patients dealing with cancer.
CLICK HERE to see Dr. Patrick Forde in our Showcase
About Johns Hopkins Medicine
Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is a $7 billion integrated global health enterprise and one of the leading health care systems in the United States. Johns Hopkins Medicine unites physicians and scientists of the Johns Hopkins University School of Medicine with the organizations, health professionals and facilities of The Johns Hopkins Hospital and Health System.
Johns Hopkins Medicine's vision, "Together, we will deliver the promise of medicine," is supported by its mission to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care. Diverse and inclusive, Johns Hopkins Medicine educates medical students, scientists, health care professionals and the public; conducts biomedical research; and provides patient-centered medicine to prevent, diagnose and treat human illness.
Johns Hopkins Medicine operates six academic and community hospitals, four suburban health care and surgery centers, and 39 primary and specialty care outpatient sites. The Johns Hopkins Hospital, opened in 1889, has been ranked number one in the nation by U.S. News & World Report for 22 years of the survey's 25-year history, most recently in 2013. For more information, visit http://www.hopkinsmedicine.org/about/
UT Southwestern Medical Center, Dallas, TX
David Gerber, MD more
David Gerber, M.D., is an Associate Professor of Internal Medicine within the Hematology/Oncology Division at UT Southwestern Medical Center and Co-Director of the Experimental Therapeutics Program.
He graduated cum laude from Yale University in New Haven, Conn., and earned his medical degree at Cornell University Medical College in New York.
He completed his internship and residency in internal medicine at UT Southwestern, followed by a fellowship in medical oncology at Johns Hopkins University School of Medicine in Baltimore.
Dr. Gerber is board certified in internal medicine and medical oncology, and he holds medical licenses in both Texas and Maryland.
He is active in research related to lung cancer, including clinical trials. His research has generated more than 100 publications that he has authored or co-authored, including articles, abstracts, book chapters, book reviews, and invited manuscripts. His studies have contributed to invitations to lecture both nationally and internationally.
CLICK HERE to see Dr. David Gerber in our Showcase
About UT Southwestern Medical Center
The story of UT Southwestern Medical Center is one of commitment to excellence, dedication to discovery, and service to the community. It's also a story of phenomenal growth, fueled by exceptional people with an extraordinary vision: to establish an academic medical center second to none.
Since its formation in 1943, Southwestern Medical School has grown from a small wartime medical college into UT Southwestern Medical Center, a multifaceted academic institution nationally recognized for its excellence in educating physicians, biomedical scientists, and health care personnel. The faculty also includes six Nobel Laureates, four of whom are active faculty members, 21 members of the prestigious National Academy of Sciences, and 19 members of the Institute of Medicine, a component of the NAS. UT Southwestern's faculty and residents annually provide care to more than 90,000 hospitalized patients and oversee nearly 2 million outpatient visits. Learn more at http://www.utsouthwestern.edu/about-us/mission-history/index.html
USC Norris Comprehensive Cancer Center, Los Angeles, CA
Barbara Gitlitz, M.D. more
Dr. Barbara J. Gitlitz, MD is an Associate Professor of Clinical Medicine at Keck Hospital of USC, Keck Medicine - Pasadena, USC Healthcare Center 2 and USC Norris Comprehensive Cancer Center and Hospital.
After graduating from the State University of New York Stony Brook campus, Dr. Gitlitz moved out west to California. After completing a fellowship in Hematology Oncology and Translational Investigation at UCLA, she stayed on as an Assistant Professor. Much of her early clinical-translational work involved cancer immunotherapy including one of the first trials of a Dendritic Cell Vaccine for patients with kidney cancer. She then joined the Keck School of Medicine of USC as an Associate Professor to spearhead the USC oncology effort in lung cancer and head and neck cancer.
Her most rewarding part of working at USC is being a member of multidisciplinary treatment teams; where medical oncologists, surgeons, radiation oncologists and other specialists can collaborate together on the best, individualized treatment plan for a patient. Her dedicated, compassionate clinical care has been noticed by the community as she has been consistently nominated to the list of Los Angeles Magazine Super Doctors, Pasadena Magazine Top Doctors, and US News Top Doctors.
She has received research grants from the American Cancer Society, the National Institute of Health and STOP cancer. She is a member of the Stand Up 2 Cancer Epigenetics Dream Team bringing novel trials to treat cancer with combinations of immunotherapy and therapy to awaken important genes that are "turned off" by growing cancers. Dr. Gitlitz has a passion for working with scientists seeking ways to personalize therapy and bring novel drugs (clinical trials) to treat her patients. She believes that each person's cancer may have unique molecular/genomic features to help guide the best treatment plan. She is the Principle Investigator for the Genomics of Young Lung international trial studying primary lung cancer afflicting patients less than age 40.
Dr. Gitlitz is an accomplished author and has numerous articles published in peer reviewed cancer journals and she has written numerous book chapters. She has been invited to lecture at cancer conferences all across the United States and internationally.
CLICK HERE to see Dr. Barbara J. Gitlitz in our Showcase
About USC Norris Comprehensive Cancer Center
The USC Norris Comprehensive Cancer Center, located in Los Angeles, is a major regional and national resource for cancer research, treatment, prevention and education.
More than 200 basic and population scientists, physicians from the faculty of the Keck School of Medicine of USC and several USC professional schools/departments and the College of Letters, Arts and Sciences who are members of the USC Norris Comprehensive Cancer Center investigate the complex origins and progression of cancer, develop prevention strategies and search for cures.
The National Cancer Institute (NCI) has designated the USC Norris Comprehensive Cancer Center as one of the nation's 41 comprehensive cancer centers, a select group of institutions providing leadership in cancer treatment, research, prevention and education. USC Norris Comprehensive Cancer Center has held this designation since 1973, when it was named as one of the first eight comprehensive cancer centers. Learn more at uscnorriscancer.usc.edu.
Vanderbilt Ingram Cancer Center, Nashville, TN
Leora Horn, M.D. more
Dr. Liu graduated cum laude from Johns Hopkins University and received his M.D. at the University of Maryland. He completed an internship and residency in Internal Medicine at the University of Pennsylvania and a fellowship in Hematology & Oncology at the University of Southern California, where he served as Chief Fellow. Dr. Liu then joined the USC faculty as an Assistant Professor of Medicine.
In 2013, he joined the faculty at Georgetown University and the Lombardi Comprehensive Cancer Center specializing in lung cancer and phase I clinical trials.
He is a practicing lung oncologist but has accumulated extensive laboratory experience with a focus on genomics and tumor evolution. He has served as Principal Investigator on several trials including an NCI sponsored, multi-institution phase I study combining targeted therapy with traditional chemotherapy for lung cancer. His funded research projects included the study of genomic changes in circulating tumor cells,
which has been nationally presented. With his specific training, Dr. Liu is well poised to serve as a translational researcher, bringing laboratory advances into the oncology clinic. His special Interests focus on lung cancer, developmental therapeutics and clinical trials.
Dr Liu attended Medical School at University of Maryland, Baltimore, MD, 2005; did his Internship at University of Pennsylvania, Philadelphia, PA, 2006; Residency at University of Pennsylvania, Philadelphia, PA, 2008 and Fellowship in Hematology/Oncology, University of Southern California, Los Angeles, CA, 2011.
His certifications include Internal Medicine, 2008; Hematology, 2011; Medical Oncology, 2011.
CLICK HERE to see Dr. Leora Horn in our Showcase
About Vanderbilt Ingram Cancer Center
Vanderbilt-Ingram Cancer Center (VICC) is a leader in the prevention, diagnosis and treatment of cancer. The center’s world-renowned team of experts provides an integrated, personalized and patient-centered approach to cancer care, including treatment, research, support, education and outreach. From a wide variety of wellness programs to a leading REACH for Survivorship Clinic, patients find support from diagnosis through survivorship. VICC is a National Cancer Institute-designated Comprehensive Cancer Center, one of just two centers in Tennessee and 41 in the country to earn this highest distinction, and ranks in the top 10 nationwide for cancer research grant support.
Built on a long-standing legacy that includes the work of Nobel laureates Stanley Cohen and Earl Sutherland, Vanderbilt-Ingram Cancer Center is focused on improving outcomes for all individuals diagnosed with cancer through collaboration and scientific innovation. Our work includes basic, translational and population-based research, cancer prevention and control, precision cancer treatment and breakthrough clinical trials, as well as community outreach, education and service. Learn more at www.vicc.org
Georgetown University Hospital Cancer Center, Washington DC
Stephen V. Liu, M.D. more
Dr. Stephen Liu is an Assistant Professor in the Division of Hematology & Oncology at the Lombardi Comprehensive Cancer Center in Georgetown University. Dr. Liu graduated cum laude from Johns Hopkins University and received his M.D. at the University of Maryland. He completed an internship and residency in Internal Medicine at the University of Pennsylvania and a fellowship in Hematology & Oncology at the University of Southern California, where he served as Chief Fellow. Dr. Liu then joined the faculty as an Assistant Professor of Medicine specializing in lung cancer and phase I clinical trials.
He is a practicing lung oncologist but has accumulated extensive laboratory experience with a focus on genomics and tumor evolution. He has served as Principal Investigator on several trials including an NCI sponsored, multi-institution phase I study combining targeted therapy with traditional chemotherapy for lung cancer. His funded research projects included the study of genomic changes in circulating tumor cells, which has been nationally presented. With his specific training, Dr. Liu is well poised to serve as a translational researcher, bringing laboratory advances into the oncology clinic. His Special Interests focus on Lung cancer, Developmental therapeutics and Clinical trials.
Dr Liu attended Medical School at University of Maryland, Baltimore, MD, 2005; did his Internship at University of Pennsylvania, Philadelphia, PA, 2006; Residency at University of Pennsylvania, Philadelphia, PA, 2008 and Fellowship at Hematology/Oncology, University of Southern California, Los Angeles, CA, 2011. His certifications include Internal Medicine, 2008; Medical Oncology, 2011.
CLICK HERE to see Dr. Stephen Liu in our Showcase
About Georgetown University Hospital Cancer Center
MedStar Georgetown University Hospital is a not-for-profit, acute-care teaching and research hospital with 609 beds located in Northwest Washington, D.C. Founded in the Jesuit principle of cura personalis—caring for the whole person—MedStar Georgetown is committed to offering a variety of innovative diagnostic and treatment options within a trusting and compassionate environment.
MedStar Georgetown’s centers of excellence include neurosciences, transplant, cancer and gastroenterology. Along with Magnet® nurses, internationally recognized physicians, advanced research and cutting-edge technologies, MedStar Georgetown’s healthcare professionals have a reputation for medical excellence and leadership. MedStar Georgetown University Hospital—Knowledge and Compassion Focused on You. Learn more at www.medstarhealth.org
University of Pittsburgh School of Medicine, Pittsburgh, PA
Liza C. Villaruz, M.D. more
Liza C. Villaruz, MD, is an Assistant Professor of Medicine at the University of Pittsburgh School of Medicine in the Division of Hematology/Oncology. She is board-certified in internal medicine, medical oncology and hematology. Dr. Villaruz's clinical expertise and research focuses on the evaluation and management of lung cancer and other thoracic malignancies. As an active member of the Lung and Thoracic Malignancies Program and the University of Pittsburgh’s Specialized Program of Research Excellence (SPORE) in lung cancer, Dr. Villaruz actively accrues and is the principal investigator of several ongoing clinical trials at the University of Pittsburgh Cancer Institute evaluating novel therapeutic approaches to the treatment of lung cancer. Her research focuses on delineating the clinical behavior of novel molecular subtypes of lung cancer, and the study of novel targeted agents for the treatment of these lung cancer molecular subtypes.
Dr. Villaruz has been awarded the Conquer Cancer Foundation of ASCO Young Investigator Award for her work on the role of microRNAs as biomarkers of chemotherapy resistance in metastatic melanoma. Dr. Villaruz received an undergraduate degree in biology at the University of Notre Dame, in Notre Dame, IN, and a medical degree at the University of Maryland School of Medicine, in Baltimore, MD. She completed her residency in internal medicine and a fellowship in hematology/oncology at the University of Pittsburgh School of Medicine, Pittsburgh, PA. Dr. Villaruz is a member of the American Society of Clinical Oncology and is an invited reviewer for medical journals such as Lung Cancer and Oncology Research. Her areas of specialization/research interests include Lung Cancer , Novel Therapies in Lung Cancer, Clinical Trials in Lung Cancer.
Her education and training include a BS from University of Notre Dame, Notre Dame, IN, 2001; MD from, University of Maryland School of Medicine, 2005, with her residency in Internal Medicine at University of Pittsburgh Medical Center, 2008, and a fellowship in Hematology/Oncology at University of Pittsburgh Cancer Institute, 2011.
CLICK HERE to see Dr. Liza C. Villaruz in our Showcase
About University of Pittsburgh School of Medicine
The University of Pittsburgh School of Medicine educates physicians who are science-based, skilled, and compassionate clinicians prepared to meet the challenges of practicing medicine in the 21st century, and educates investigators who are prepared to conduct cutting-edge biomedical research focused on bettering the human condition and advancing the fundamental understanding of medical science. Learn more at www.medschool.pitt.edu
UNC Lineberger Cancer Center, Chapel Hill, NC
Jared Weiss, M.D. more
Dr. Jared Weiss is an assistant professor of medicine for hematology/oncology at the University of North Carolina School of Medicine in Chapel Hill, NC.
Dr Weiss received his B.S. in neuroscience at Brown University in Providence, RI; his Doctor of Medicine at Yale University School of Medicine in New Haven, CT; his residency in Internal Medicine at Beth Israel Deaconess Medical Center in Boston, MA; and his fellowship at the Hospital of the University of Pennsylvania. He is board certified in internal medicine, hematology and oncology. Dr. Weiss is an active clinical investigator in thoracic and head/neck cancers. He volunteers and advocates with the Lung Cancer Initiative of North Carolina and serves on their board of directors. He is Vice President of cancergrace.org and serves on the executive board of the Lung Cancer Initiate of North Carolina. He is the section chief of thoracic oncology at the University of North Carolina.
CLICK HERE to see Dr. Jared Weiss in our Showcase
About the UNC Lineberger Cancer Center
One of the leading cancer centers in the nation, UNC Lineberger Comprehensive Cancer Center is located in Chapel Hill, North Carolina. As one of only 41 National Cancer Institutes, UNC Lineberger was rated as exceptional - the highest category - by the National Cancer Institute. The center brings together some of the most exceptional physicians and scientists in the country to investigate and improve the prevention, early detection and treatment of cancer. With research that spans the spectrum from the laboratory to the bedside to the community, UNC Lineberger faculty work to understand the causes of cancer at the genetic and environmental levels, to conduct groundbreaking laboratory research, and to translate findings into pioneering and innovative clinical trials. Learn more at www.unclineberger.org
Swedish Cancer Institute, Seattle, WA
Howard (Jack) West, M.D. more
Dr. West practices at the Swedish Cancer Institute in Seattle, WA.
He trained at the prestigious Harvard Medical School, MA and did his residency at Brigham and Women's Hospital, with fellowship(s) at University of Washington, WA in Medical Oncology, and Fred Hutchinson Cancer Research Center, WA. He is board Certified in Oncology.
He has been voted a "Top Doctor" in both Oncology and Thoracic oncology multiple times over the past several years, in both Seattle Metropolitan and Seattle Magazine.
His positions include Founder & President, Global Resource for Advancing Cancer Education (GRACE); Web Editor for JAMA Oncology; Medical Director, Thoracic Oncology Program, Swedish Cancer Institute; Medical Director, Genitourinary Oncology Program, Swedish Cancer Institute; and Medical Oncologist, Swedish Cancer Institute. He has had faculty appointments as Affiliate Investigator, Fred Hutchinson Cancer Research Center and Acting Instructor, Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance.
His professional affiliations include Southwest Oncology Group (Lung & Early Therapeutics), King County Medical Society, Washington State Medical Society, American Association for Cancer Research, International Association for the Study of Lung Cancer, Washington State Medical Oncology Society, and the American Society of Clinical Oncology. He is prolific author and accomplished presenter.
Dr West’s philosophy of care: “My primary goal is to provide optimal balance of appropriate, aggressive treatment and a good quality of life. This requires individualized plans based on a patient's particular goals and medical issues.”
CLICK HERE to see Dr. Howard (Jack) West in our Showcase
About the Swedish Cancer Institute
As a Seattle-area leader in diagnosis, treatment and recovery since 1932, the Swedish Cancer Institute (SCI) cancer care network offers services to help you fight cancer—and win. Our team includes a host of oncologists—doctors focused exclusively on the care and treatment of cancer, using medication, radiation and other therapies.
At our locations in and around the greater Seattle area, we work in a collaborative, multidisciplinary environment that focuses on the patient—not the disease. And even though we use some of the most advanced technologies and procedures, we also offer a wide range of complementary treatments and services that address your psychological, emotional and spiritual needs.
The Swedish Cancer Institute has a new weapon in the fight against cancer. It's called personalized medicine -- the biggest news in cancer treatment in years. Learn more at www.swedish.org/services/cancer-institute